MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer

Wang, Jian; Du, Ye; Liu, Xiaoming; Cho, William C.; Yang, Yinxue

doi:10.1155/2015/823620

Cited by 50 publications

(56 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs play a key role in many crucial biological processes such as cell proliferation, differentiation, and apoptosis in colon cancer, and continued efforts will help identify new targets for the diagnosis, prognosis, and management of colon cancer [8, 16, 17]. Recently, miR-663a, which belongs to the primate specific miRNAs, was detected as a tumor suppressing miRNA in several cancer cells including colon cancer cells [18–20].…”

Section: Discussionmentioning

confidence: 99%

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

et al. 2017

View full text Add to dashboard Cite

BackgroundAntimicrobial peptides (AMPs) play important roles in the innate immune system of all life forms and recently have been characterized as multifunctional peptides that have a variety of biological roles such as anticancer agents. However, detailed mechanism of antimicrobial peptides on cancer cells is still largely unknown.MethodsmiRNA array and real-time qPCR were performed to reveal the behavior of miRNA in colon cancer HCT116 cells during the growth suppression induced by the AMPs. Establishment of miR-663a over-expressing HCT116 cells was carried out for the evaluation of growth both in vitro and in vivo. To identify the molecular mechanisms, we used western blotting analysis.ResultsmiR-663a is upregulated by administration of the human cathelicidin AMP, LL-37, and its analogue peptide, FF/CAP18, in the colon cancer cell line HCT116. Over-expression of miR-663a caused anti-proliferative effects both in vitro and in vivo. We also provide evidence supporting the view that these effects are attributed to suppression of the expression of the chemokine receptor CXCR4, resulting in the abrogation of phosphorylation of Akt and cell cycle arrest in G2/M via p21 activation.ConclusionsThis study contributes to the understanding of the AMPs’ mediated anti-cancer mechanisms in colon cancer cells and highlights the possibility of using AMPs and miRNAs towards developing future strategies for cancer therapy.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-3003-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several lines of evidence have revealed that a network of miRNAs is involve in the pathogenesis of CRC (Martín‐Subero & Esteller, ; Trang et al, ). Deregulation of these molecules could lead to inhibition and/or activation of several cellular and molecular targets that trigger development of CRC (Wang, Du, Liu, Cho, & Yang, ).…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer

Moridikia

Mirzaei

Sahebkar

et al. 2017

Journal Cellular Physiology

179

168

View full text Add to dashboard Cite

Colorectal cancer (CRC) is known as the third common cancer worldwide and an important public health problem in different populations. Several genetics and environmental risk factors are involved in the development and progression of CRC including chromosomal abnormalities, epigenetic alterations, and unhealthy lifestyle. Identification of risk factors and biomarkers could lead to a better understanding of molecular pathways involved in CRC pathogenesis. MicroRNAs (miRNAs) are important regulatory molecules which could affect a variety of cellular and molecular targets in CRC. A large number of studies have indicated deregulations of some known tissue-specific miRNAs, for example, miR-21, miR-9, miR-155, miR-17, miR-19, let-7, and miR-24 as well as circulating miRNAs, for example, miR-181b, miR-21, miR-183, let-7g, miR-17, and miR-126, in patients with CRC. In the current review, we focus on the findings of preclinical and clinical studies performed on tissue-specific and circulating miRNAs as diagnostic biomarkers and therapeutic targets for the detection of patients at various stages of CRC.

show abstract

“…Therefore, the assessment of prognostic factors is pivotal for the management of unresectable colorectal cancer patients. Several underlying mechanisms have been described in the past decades, including multiple molecular alterations, which confer the tumorigenesis and progression of colorectal cancer [13–18]. However, the exact underlying molecular markers for survival assessment of colorectal cancer remain largely unknown.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma

Zeng

Liang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Growing evidence has shown that long non-coding RNAs (lncRNAs) can serve as prospective markers for survival in patients with colorectal adenocarcinoma. However, most studies have explored a limited number of lncRNAs in a small number of cases. The objective of this study is to identify a panel of lncRNA signature that could evaluate the prognosis in colorectal adenocarcinoma based on the data from The Cancer Genome Atlas (TCGA). Altogether, 371 colon adenocarcinoma (COAD) patients with complete clinical data were included in our study as the test cohort. A total of 578 differentially expressed lncRNAs (DELs) were observed, among which 20 lncRNAs closely related to overall survival (OS) in COAD patients were identified using a Cox proportional regression model. A risk score formula was developed to assess the prognostic value of the lncRNA signature in COAD with four lncRNAs (LINC01555, RP11-610P16.1, RP11-108K3.1 and LINC01207), which were identified to possess the most remarkable correlation with OS in COAD patients. COAD patients with a high-risk score had poorer OS than those with a low-risk score. The multivariate Cox regression analyses confirmed that the four-lncRNA signature could function as an independent prognostic indicator for COAD patients, which was largely mirrored in the validating cohort with rectal adenocarcinoma (READ) containing 158 cases. In addition, the correlative genes of LINC01555 and LINC01207 were enriched in the cAMP signaling and mucin type O-Glycan biosynthesis pathways. With further validation in the future, our study indicates that the four-lncRNA signature could serve as an independent biomarker for survival of colorectal adenocarcinoma.

show abstract

MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer

Cited by 50 publications

References 120 publications

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer

Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma

Contact Info

Product

Resources

About